The APAC Autoimmune Hemolytic Anemia (AIHA) market is expected to grow as a result of the increased prevalence of AIHA in the APAC region. The market is segmented by disease type, therapy type, drugs, and by route of administration. AstraZeneca and Roche are some of the key players in the APAC AIHA market.
The APAC EHR market is projected to grow from $5.94 Bn in 2022 to $8.96 Bn in 2030 with a CAGR of 5.27% for the year 2022-2030. The introduction of artificial intelligence in the advancement of EHR has significantly contributed to the growth of the market. McKesson Corporation and Oracle Cerner Corporation are the major players in the APAC EHR market.